Fasoracetam 99% White solid powder

Product name: (R)-1-[(5-oxo-2-pyrrolidinyl)carbonyl] piperidine; N-(5-oxo-D-prolyl)piperidine;NS-105;LAM-105
CAS:110958-19-5
Molecular Formula:C10H16N2O2
Molecular Weight:196.25
Purity:99%
Appearance:White solid powder
Package:1kg/bag
Use: Nootropic

What is Fasoracetam?
Fasoracetam is a powerful Racetam compound with a chemical structure of (5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one.Primarily it has attracted the interest of nootropics enthusiasts searching for ever stronger analogues of the original racetam, Piracetam.
Fasoracetam improves general intelligence while attacking anxiety and apathy, which, as much as a lack of ability, can stand in the way of reaching one’s full potential.These are also frequent concerns for patients diagnosed with ADHD which explains the interest in researching its effects for this disorder.
Fasoracetam prevents learned helplessness. In animal trials, rats given the drug were substantially less likely to remain immobile when submersed in water than those who were not. They were also more motivated to rescue themselves from merciless electrical shocks on their feet.
While human studies have yet to be conducted in this area, it was found to increase “the number of GABAB receptors in rat cerebral cortex without affecting the binding properties of adrenoceptors and 5-HT2 receptors.”

How does it work?
The brain does not build a tolerance to fasoracetam; each dose is as or more effective at alleviating depression and anxiety as the last. Its mechanism of action is not like Prozac’s.
Nor does it affect monoamine uptake or its circulating concentration within tissues. Its short term safety has been established, but it is not certain whether it is as well tolerated long term as Piracetam or Aniracetam.

Description:
Fasoracetam, also known as NS-105; NFC-1; LAM-105, is a GABA receptor modulator potentially for the treatment of attention deficit hyperactivity disorder. It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder. In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity. In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist and upregulated production of GABAB receptors after repeat dosing.